

Molecular Therapeutics of Cancer Research Conference -- 2010

Co-Sponsored by the Cancer Molecular Therapeutics Research Association
& the Department of Molecular Biology at Princeton University

Schedule and Program

(as of July 8, 2010)

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

**NOTE: ALL SCIENTIFIC SESSIONS WILL BE HELD AT Lewis Thomas Lab (LTL 003);
Dorms will be at Forbes College**

SUNDAY – JULY 18

3:00 pm	Arrival and check-in (Forbes College)
6:00 – 7:30 pm	Reception / Buffet Dinner (Forbes College)
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, President CMTRA Robert Kramer, BMS John S. Lazo, Program Chair
7:45 – 10:00 pm	EVENING SESSION: "Synthetic Lethal or Lethal Synthetics?" Discussion Leader: Jim Broach, Princeton University
7.45 – 8:00 pm	Introduction & Overview
8:00 – 8.40 pm	Speaker – D. Gary Gilliland, Merck & Co. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
8:40 – 9:00 pm	Discussion
9:00 – 9:40 pm	Speaker – Lars Zender, Helmholtz Centre for Infection Research Integrative Oncogenomic approaches for accelerated cancer gene discovery in Liver Cancer
9:40 – 10:00 pm	Discussion
10:00 pm –	Social (Forbes College)

MONDAY – JULY 19

7:00 – 8:00 am	Breakfast (Rocky Dining Hall)
8:15 – 12:00 pm	MORNING SESSION: "Predictive Biomarkers and Patient Selection-How Deep Do We Go?" Discussion Leader: Branimir I. Sikic, Stanford University
8:15 – 8:30 am	Introduction

8:30 – 9:10 am	Speaker – Angela DeMichele, MD, MSCE, Associate Professor of Medicine and Epidemiology, University of Pennsylvania Perelman Center The I-SPY 2 Trial: a new paradigm for therapeutic biomarker development
9:10 – 9:30 am	Discussion
9:30 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:40 am	Speaker – Keith Baggerly, UT M.D. Anderson Cancer Center The importance of reproducibility in high-throughput biology: Case studies in forensic bioinformatics.
10:40 – 11:00 am	Discussion
11:00 – 11:40 am	Speaker – Tim Yeatman, Executive Vice President Translational Research, President & Chief Scientific Officer, M2Gen The value-added of private-public partnerships to a Comprehensive Cancer Center.
11:40 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i> (Rocky Dining Hall)
2:00 – 4:30 pm	AFTERNOON SESSION: “Beyond the Numbers: Circulating Tumor Cells” Discussion Leader: Caroline Dive, The Paterson Institute for Cancer Research
2:00 – 2:15 pm	Introduction
2:15 – 2:55 pm	Speaker – Howard I. Scher, Memorial Sloan Kettering Cancer Center Circulating tumor cells as biomarkers: Validation and qualification in the context of unmet medical needs.
2:55 – 3:15 pm	Discussion
3:15 – 3:55 pm	Speaker – Stefanie S. Jeffrey, Stanford University Molecular Analyses of Circulating Tumor Cells: Implications for Personalized Therapy
3:55 – 4:15 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social (Forbes College)
6:00 – 6:30 pm	<i>Dinner</i> (Rocky Dining Hall)
7:30 – 9:45 pm	EVENING SESSION: “Tumor Metabolism” Discussion Leader: Mary-Ann Bjornsti, UAB
7.30 – 7:45 pm	Introduction
7:45 – 8:25 pm	Speaker – Chi Dang, Johns Hopkins University Rethinking the Warburg Effect with Myc micromanaging glutamine metabolism.
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Speaker – John Hartman IV, University of Alabama at Birmingham Buffering of deoxyribonucleotide pool homeostasis by threonine metabolism .
9:25 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i> (Forbes College)

TUESDAY JULY 20

7:00 – 8:00 am	<i>Breakfast</i> (Rocky Dining Hall)
8:15 – 12:00 pm	MORNING SESSION: “Harnessing the Immune System to Treat Solid Tumors” Discussion Leader: Olja Finn, Pitt
8:15 – 8:30 am	Introduction
8:30 – 9:10 am	Speaker – Rachel Humphrey, Bristol Myers Squibb Antibodies: CTLA-4 Antagonist Development for Cancer
9:10 – 9:30 am	Discussion
9:30 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:40 am	Speaker – George C. Prendergast, Professor and President/CEO Lankenau Institute for Medical Research IDO pathway of immune escape in cancer
10:40 – 11:00 am	Discussion
11:00 – 11:40 am	Speaker – Drew Pardoll, Johns Hopkins University The immune microenvironment of the tumor as target for cancer therapeutics.
11:40 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i> (Rocky Dining Hall)
12:00 – 4.30 pm	NETWORKING AFTERNOON Princeton University Campus
4:30 – 6:00 pm	Poster Session and Social (Forbes College)
6:00 – 6:30 pm	BBQ Dinner (Forbes College)
7:30 – 9:45 pm	EVENING SESSION: “Targeting Cancer Redox Nodes” Discussion Leader: Sara Courtneidge, Sanford-Burnham Medical Research Institute, La Jolla, CA
7:30 – 7:45 pm	Introduction
7:45 – 8:25 pm	Speaker – J. Alan Diehl, Professor of Cancer Biology. University of Pennsylvania Mediating Redox Homeostasis and Tumor Progression from the Endoplasmic Reticulum.
8:25 – 8:45 pm	Discussion
8:45 – 9:25 pm	Speaker – Giovanni Melillo, M.D., Senior Investigator, Developmental Therapeutics Program, SAIC Frederick Inc., National Cancer Institute, Frederick, MD Targeting HIF-1 for Cancer Therapy.
9:25 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i> (Forbes College)

WEDNESDAY JULY 21

- 7:00 – 8:00 am *Breakfast* (Rocky Dining Hall)
- 8:15 – 11:00 am **MORNING SESSION: “Modern Animal Models of Cancer”**
Discussion Leader: Phillip Dennis, NCI
- 8:15 – 8:30 am Introduction
- 8:30 – 9:10 am Speaker – Heiner Fiebig, Professor of Medical Oncology, University of Freiburg, CEO Oncotest Institute GmbH.
Patient derived tumor models, relevance for drug discovery and identification of predictive gene signatures.
- 9:10 – 9:30 am Discussion
- 9:30 – 10:00 am *Coffee Break*
- 10:00 – 10:40 am Speaker – Charles Keller, Associate Professor, Department of Pediatrics Oregon Health & Science University
Interleukin-4 Receptor as a novel therapeutic target in childhood muscle cancer.
- 10:40 – 11:00 am Discussion
- 11:00 – 12:00 pm **POSTER PRESENTATIONS – Four Selected Presenters**
- 12:00 – 1:00pm *Lunch* (Rocky Dining Hall)
- 2:00 – 5:45 pm **AFTERNOON SESSION: “Proapoptotic Pathways-Is targeting Death Dead?”**
Discussion Leader: John A. Hickman, Servier, Paris, France
- 2:00 – 2:15 pm Introduction
- 2:15 – 2:55 pm Speaker – Ingrid Wertz, Department of Protein Engineering, Genentech, Inc.
Insights to cell death targeting strategies from the ubiquitin system.
- 2:55 – 3:15 pm Discussion
- 3:15 – 3:45 pm *Coffee Break*
- 3:45 – 4:25 pm Speaker – Dale Porter, Novartis Institutes for BioMedical Research.
Targeting inhibitors of apoptosis proteins.
- 4:25 – 4:45 pm Discussion
- 4:45 – 5:25 pm Speaker – Steve Elmore, Cancer Research, Abbott Laboratories.
Flipping the death switch in cancer: Targeting Bcl-2 family proteins.
- 5:25 – 5:45 pm Discussion
- 6:00 – 10:00 pm ***Farewell Banquet (Prospect House)***

THURSDAY JULY 22

- 7:00 - 8:00 am *Breakfast* (Rocky Dining Hall)
CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

Amgen
AztraZeneca
Bristol-Myers Squibb
Lilly
Novartis
Ortho (J&J)
Pfizer
Roche

MOLECULAR THERAPEUTICS OF CANCER 2011 CONFERENCE

July 10-14, 2011 at the Asilomar, Pacific Grove, CA

Program Chair: Sara Courtneidge

Site Chair: tbd